Edition:
India

Aclaris Therapeutics Inc (ACRS.OQ)

ACRS.OQ on NASDAQ Stock Exchange Global Select Market

17.79USD
1:30am IST
Change (% chg)

$0.06 (+0.34%)
Prev Close
$17.73
Open
$17.68
Day's High
$17.85
Day's Low
$17.62
Volume
65,797
Avg. Vol
128,539
52-wk High
$30.06
52-wk Low
$16.24

Chart for

About

Aclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and... (more)

Overall

Beta: --
Market Cap(Mil.): $828.20
Shares Outstanding(Mil.): 30.00
Dividend: --
Yield (%): --

Financials

BRIEF-Aclaris Therapeutics Names Bryan Reasons Director And Chairman, Audit Committee

* ACLARIS THERAPEUTICS ANNOUNCES APPOINTMENT OF BRYAN REASONS AS A DIRECTOR AND CHAIRMAN OF THE AUDIT COMMITTEE Source text for Eikon: Further company coverage:

25 Apr 2018

BRIEF-Aclaris Says Primary, Secondary, And Exploratory Endpoints Of Phase 2 Trial of A-101 45% Met

* ACLARIS THERAPEUTICS ANNOUNCES POSITIVE UPDATE ON PHASE 2 RESULTS AFTER A 3-MONTH FOLLOW-UP OF A-101 45% TOPICAL SOLUTION FOR POTENTIAL TREATMENT OF COMMON WARTS

19 Mar 2018

BRIEF-Aclaris Therapeutics Q4 Revenue $1.0 Mln

* ACLARIS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS

12 Mar 2018

BRIEF-Aclaris Therapeutics Issues U.S. Patent Covering JAK Inhibitor For Treating Hair Loss Disorders

* ACLARIS THERAPEUTICS ANNOUNCES ISSUANCE OF U.S. PATENT COVERING A JAK INHIBITOR FOR TREATING HAIR LOSS DISORDERS Source text for Eikon: Further company coverage:

09 Mar 2018

BRIEF-Aclaris Therapeutics Signs Agreement With James Alexander Corp

* ACLARIS THERAPEUTICS SAYS ON JAN 24, CO ENTERED INTO COMMERCIAL SUPPLY MANUFACTURING SERVICES AGREEMENT WITH JAMES ALEXANDER CORP - SEC FILING

31 Jan 2018

BRIEF-Aclaris Therapeutics' A-101 45% Topical Solution Meets Primary, All Secondary Endpoints In Two Phase 2 Clinical Trials For Common Warts

* ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS

08 Jan 2018

Aclaris's drug to treat common skin growth gets FDA nod

Aclaris Therapeutics Inc's drug to treat a common kind of skin growth called seborrheic keratoses received approval from the U.S. Food and Drug Administration, the company said on Friday.

15 Dec 2017

UPDATE 2-Aclaris's drug to treat common skin growth gets FDA nod

Dec 15 Aclaris Therapeutics Inc's drug to treat a common kind of skin growth called seborrheic keratoses received approval from the U.S. Food and Drug Administration, the company said on Friday.

15 Dec 2017

Aclaris's drug to treat common growth on skin gets FDA nod

Dec 15 Aclaris Therapeutics Inc said on Friday the U.S. Food and Drug Administration (FDA) had approved its topical drug to treat seborrheic keratoses, growths on the skin that are harmless but affect millions of Americans.

15 Dec 2017

BRIEF-Aclaris Therapeutics Receives FDA Approval For Eskata For Treatment Of Raised SKs

* ACLARIS THERAPEUTICS RECEIVES FDA APPROVAL FOR ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W) FOR THE TREATMENT OF RAISED SEBORRHEIC KERATOSES (SKS)

15 Dec 2017

Competitors

  Price Chg
RXi Pharmaceuticals Corp (RXII.OQ) $2.65 +0.01

Earnings vs. Estimates